...
首页> 外文期刊>Human Pathology >Serous papillary adenocarcinoma of the female genital organs and invasive micropapillary carcinoma of the breast. Are WT1, CA125, and GCDFP-15 useful in differential diagnosis?
【24h】

Serous papillary adenocarcinoma of the female genital organs and invasive micropapillary carcinoma of the breast. Are WT1, CA125, and GCDFP-15 useful in differential diagnosis?

机译:女性生殖器浆液性乳头状腺癌和乳腺浸润性微乳头状癌。 WT1,CA125和GCDFP-15在鉴别诊断中有用吗?

获取原文
获取原文并翻译 | 示例
           

摘要

Serous papillary adenocarcinoma of the female genital organs and invasive micropapillary carcinoma of the breast have close histologic similarities. Thus, when these cancers occur synchronously or metachronously in the same patient, it is difficult to determine the primary site. We examined 23 serous papillary adenocarcinomas (16 ovarian, 5 endometrial, and 2 peritoneal) and 37 invasive micropapillary carcinomas of the breast (12 pure and 25 mixed types) on immunohistochemical expression of Wilm's tumor antigen-1 (WT1), CA125, and gross cystic disease fluid protein-15 (GCDFP-15), which have been reported to be useful in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary. The positive rates of WT1, CA125, and GCDFP-15 in serous papillary adenocarcinomas were 78%, 78%, and 0%, respectively, and the corresponding rates in invasive micropapillary carcinomas were 3%, 40%, and 38%. The CA125-positive rate of invasive micropapillary carcinoma was higher than the rate reported for other types of breast carcinomas. We consider CA125 to be not always useful in the differential diagnosis of serous papillary adenocarcinoma and invasive micropapillary carcinoma. Although the positive rate of WT1 was significantly higher in serous papillary adenocarcinoma than in invasive micropapillary carcinoma, WT1 expression in endometrial serous papillary adenocarcinoma was infrequent (20%). WT1 and GCDFP-15 could be useful markers for the differential diagnosis of ovarian and peritoneal serous papillary adenocarcinoma versus breast invasive micropapillary adenocarcinoma. However, the availability of GCDFP-15 is limited because of the low positive rate of GCDFP-15 in invasive micropapillary carcinomas.
机译:女性生殖器浆液性乳头状腺癌与乳腺浸润性微乳头状癌在组织学上有相似之处。因此,当这些癌症在同一患者中同步或同时发生时,很难确定主要部位。我们检查了23种浆液性乳头状腺癌(16个卵巢癌,5个子宫内膜癌和2个腹膜癌)和37个乳腺浸润性微乳头状癌(12种纯种和25种混合型)对Wilm肿瘤抗原-1(WT1),CA125和大肠癌的免疫组织化学表达的影响囊性疾病液蛋白15(GCDFP-15),据报道可用于对原发性卵巢癌与卵巢转移性乳腺癌的鉴别诊断。浆液性乳头状腺癌中WT1,CA125和GCDFP-15的阳性率分别为78%,78%和0%,浸润性微乳头状癌的相应率分别为3%,40%和38%。浸润性微乳头状癌的CA125阳性率高于其他类型乳腺癌的报道率。我们认为CA125在浆液性乳头状腺癌和浸润性微乳头状癌的鉴别诊断中并不总是有用。尽管浆液性乳头状腺癌中WT1的阳性率明显高于浸润性微乳头状癌,但子宫内膜浆液性乳头状腺癌中WT1的表达很少(20%)。 WT1和GCDFP-15可能是鉴别卵巢和腹膜浆液性乳头状腺癌与乳腺浸润性微乳头状腺癌的有用标志物。然而,由于在浸润性微乳头状癌中GCDFP-15的阳性率低,因此GCDFP-15的可用性受到限制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号